Evidence map›Paper›PMID 42802811›Full record

ArticleEClinicalMedicine2026

Sex differences in tuberculosis incidence: a pooled analysis of 11 prospective cohort studies.

Yohhei Hamada, Sujen Surenthirarajah, Rishi K Gupta, Matteo Quartagno, Carlos Acuna-Villaorduna, Neus Altet, Roland Diel, Jose Dominguez, Sian Floyd, Amita Gupta and 16 more

Abstract read
In one paragraph

Article in EClinicalMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Yohhei HamadaInstitute for Global Health, University College London, London, United Kingdom.
Sujen SurenthirarajahInstitute for Global Health, University College London, London, United Kingdom.
Rishi K GuptaInstitute for Global Health, University College London, London, United Kingdom.
Matteo QuartagnoMRC Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, London, United Kingdom.
Carlos Acuna-VillaordunaBoston University Medical Center, Section of Infectious Diseases, Boston, MA, USA.
Neus AltetUnitat de Tuberculosis, Hospital Universitari Vall d'Hebron-Drassanes, Unitat de TDO de la Tuberculosis 'Servicios Clínicos', Barcelona, Spain.
Roland DielInstitute for Epidemiology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Jose DominguezInstitut d'Investigació Germans Trias i Pujol, CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Universitat Autònoma de Barcelona, Barcelona, Spain.
Sian FloydDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom.
Amita GuptaJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Edward C Jones-LópezDivision of Infectious Diseases, Department of Medicine, Keck School of Medicine of USC, University of Southern California, CA, USA.
Christoph LangeDivision of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany.
Frank van LethDepartment of Health Sciences, VU University, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.
Irene Latorre RuedaInstitut d'Investigació Germans Trias i Pujol, CIBER Enfermedades Respiratorias, Instituto de Salud Carlos III, Universitat Autònoma de Barcelona, Barcelona, Spain.
Vidya MaveByramjee Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, Maharashtra, India.
Laura MuñozDepartment of Clinical Sciences, University of Barcelona, Barcelona, Spain.
Mandar ParadkarByramjee Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, Maharashtra, India.
Martina SesterDepartment of Transplant and Infection Immunology, Saarland University, Homburg, Germany.
Haridas PrasadByramjee Jeejeebhoy Government Medical College and Sassoon General Hospital, Pune, Maharashtra, India.
Kwame ShanaubeZambart, Lusaka, Zambia.
Surendra K SharmaDepartment of Internal Medicine, All India Institute of Medical Sciences, New Delhi, India.
Rosa SlootDesmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Giovanni SotgiuClinical Epidemiology and Medical Statistics Unit Department of Medicine, Surgery and Pharmacy, University of Sassari, Sassari, Italy.
Richa VashishthaDepartment of Internal Medicine, All India Institute of Medical Sciences, New Delhi, India.
Ibrahim AbubakarFaculty of Population Health Sciences, University College London, London, United Kingdom.
Molebogeng X RangakaInstitute for Global Health, University College London, London, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tuberculosis (TB) incidence is consistently higher in men than women globally. Whether this disparity arises from differential infection risk or sex-specific rates of progression from infection to disease remains unclear. We evaluated sex differences in the development of TB disease while accounting for baseline infection status. Methods: We conducted a pooled individual participant data analysis of 11 prospective cohort studies (n = 22,424), conducted between 2005 and 2017 across Sub-Saharan Africa, Europe, Asia, and South America. TB infection was defined by a positive QuantiFERON-TB Gold In-Tube result, and incident TB was defined by bacteriologically confirmed or clinical diagnosis. We used mixed-effects logistic and Cox proportional hazards models, adjusted for age, to estimate odds ratios (OR) for infection and hazard ratios (HR) for incident TB by sex. Findings: Participants were followed for a median of 2.8 years, during which 411 individuals (1.8%) developed TB. Most participants were from Europe (52%) or South Africa/Zambia (34.4%). At baseline, males had a significantly higher likelihood of infection (OR 1.12; 95% CI 1.02-1.22). Among those with baseline infection, pooled incidence rates were 16.3 per 1000 person-years (95% CI 10.9-24.4) in females and 15.6 (95% CI 9.8-24.8) in males. The risk of developing TB did not differ by sex among those with baseline infection (HR 0.86; 95% CI 0.65-1.14) or without baseline infection (HR 1.02; 95% CI 0.71-1.47). Interpretation: In these cohorts, males had a higher prevalence of baseline TB infection, but no clear excess risk of subsequent TB disease after accounting for baseline infection status. These findings suggest that sex differences in TB infection risk may contribute more to higher TB incidence among males than differences in TB disease risk after infection. Funding: None.

Indexed as

Disease progressionEpidemiologic factorsLatent tuberculosisProspective cohort studiesSex factorsTuberculosis

Identifiers

PMID42802811
PMCPMC13616561

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.